Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

Safety Assessment Program has published peer-reviewed safety assessments covering over 2,000 fragrance materials in the peer-reviewed ...

On behalf of our Board and leadership team, we are delighted to have Mike join our Board of Directors,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “His ...

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

AstraZeneca Plc and Daiichi's breast cancer drug Enhertu is based off of Daiichi's antibody-drug conjugate platform DXd, and ...

The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.

AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...

AbbVie is one of my most successful investments, but I only buy it when the dividend yield nears 4%. AbbVie is a terrific ...